While these do not predict exact medication response, they may help your provider contextualize your metabolic profile and decide whether liraglutide, semaglutide, tirzepatide, or another approach aligns with your genetics and health goals
Prof Ralph DeFronzo) advocated dual and triple therapy: start patients on low doses of one or two complementary pleiotropic agents and titrate over time and on the basis of increasing HbA1c
In these situa-tions, care should not be delayed. Anesthesiologists Have the Final Say Following the AGA clinical update, Ali Rezaie, MD, director of the GI motility program at Cedars Sinai in Los Angeles, recalled there being tension among all those involved in managing preoperative care for GLP-1 users
Wu C-Y, Shapiro L, Ouk M et al (2022) Glucose-lowering drugs, cognition, and dementia: the clinical evidence
Research into GLP-1 and other obesity treatments is evolving quickly